GO:0070256 negative regulation of mucus secretion: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070256 (negative regulation of mucus secretion) describes any process that stops, prevents, or reduces the regulated release of mucus from a cell or tissue.
• Mucus secretion is a tightly controlled innate immune barrier function; its negative regulation prevents airway obstruction and excessive mucus plugging in asthma and COPD.
• Key regulatory nodes include CD39+CD9+ lung interstitial macrophages that suppress IL-23/Th17-mediated neutrophilic asthma and NETosis.
• SLAMF7 signaling regulates goblet cell mucus production and negatively impacts gut homeostasis and commensalism.
• Metrnl/IL-41 inhibits macrophage extracellular traps and suppresses airway remodeling in asthma, providing a brake on mucus hypersecretion.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to causally test genes that negatively regulate mucus secretion.
Description
GO:0070256, negative regulation of mucus secretion, is a biological process term in the Gene Ontology that captures any mechanism that stops, prevents, or reduces the frequency, rate, or extent of regulated mucus release from a cell or tissue. Mucus is a viscoelastic secretion rich in mucins, and its overproduction is a hallmark of chronic airway diseases such as asthma and COPD. Understanding the negative regulators of mucus secretion is therefore central to therapeutic strategies aimed at restoring mucosal homeostasis. Recent studies have identified distinct immune and epithelial cell populations that actively suppress mucus secretion. For example, CD39+CD9+ lung interstitial macrophages suppress IL-23/Th17-mediated neutrophilic asthma by inhibiting NETosis, thereby limiting mucus hypersecretion. In the gut, SLAMF7 regulates goblet cell mucus production and negatively impacts gut homeostasis and commensalism. These findings highlight that negative regulation of mucus secretion is an active, genetically encoded process rather than a passive default state. For researchers, GO:0070256 provides a framework to annotate genes and pathways that restrain mucus output, with direct relevance to asthma, COPD, ulcerative colitis, and irradiation-induced intestinal injury. This article integrates authoritative QuickGO data with verified PubMed literature to deliver a research-grade overview of the term, its mechanisms, key genes, disease links, and CRISPR-based methods for functional validation.
negative regulation of mucus secretion At A Glance
| GO ID | GO:0070256 |
|---|---|
| GO term | negative regulation of mucus secretion |
| Ontology | biological_process |
| Synonym | negative regulation of mucus production |
| Definition | Any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of mucus from a cell or a tissue. |
| Major function | Suppression of mucin exocytosis and mucus layer formation to prevent airway obstruction and maintain mucosal homeostasis. |
| Related processes | Regulation of mucus secretion (GO:0070254); positive regulation of mucus secretion (GO:0070255); mucin biosynthesis; goblet cell differentiation. |
| Key cell types | Goblet cells, lung interstitial macrophages, airway epithelial cells, intestinal epithelial cells. |
| Disease relevance | Asthma, COPD, ulcerative colitis, irradiation-induced intestinal injury. |
What Is GO:0070256?
According to the Gene Ontology, GO:0070256 (negative regulation of mucus secretion) is defined as any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of mucus from a cell or a tissue. The synonym negative regulation of mucus production is also used. This term is a biological process and is distinct from positive regulation of mucus secretion (GO:0070255) and regulation of mucus secretion (GO:0070254). It encompasses signaling events, transcriptional programs, and cellular interactions that suppress mucin exocytosis or mucus layer formation.
Why Is negative regulation of mucus secretion Important in Cell Biology?
Negative regulation of mucus secretion is critically important because excessive mucus production contributes to airway obstruction, impaired gas exchange, and increased morbidity in asthma and COPD. In the intestine, uncontrolled mucus secretion can disrupt the mucus barrier and alter commensal homeostasis, as shown for SLAMF7. Understanding the negative regulators of mucus secretion provides therapeutic targets to dampen mucus hypersecretion without compromising essential barrier function.
• Prevents airway mucus plugging and obstruction in asthma and COPD.
• Maintains intestinal mucus barrier homeostasis and commensalism.
• Limits IL-23/Th17-mediated neutrophilic inflammation in the lung.
• Suppresses NETosis and macrophage extracellular trap formation.
• Protects against irradiation-induced intestinal injury via microbial metabolites.
• Provides a mechanistic brake on goblet cell metaplasia and hyperplasia.
• Offers targets for plant-derived exosome-like nanovesicles in ulcerative colitis therapy.
• Guides CRISPR-based functional genomics of mucus-regulatory genes.
• Informs primary atopic disorder diagnosis through genomic sequencing.
• Supports development of anti-mucus therapies in chronic airway diseases.
What Happens During negative regulation of mucus secretion?
Initiation by immune cell sensing
In simple terms: Immune cells detect danger signals and start a program that reduces mucus release.
Negative regulation of mucus secretion is initiated when specialized immune cells sense inflammatory cues. CD39+CD9+ lung interstitial macrophages suppress IL-23/Th17-mediated neutrophilic asthma by inhibiting NETosis, which in turn reduces mucus hypersecretion. This macrophage population acts as a negative regulator of the mucus secretion pathway.
Signal transduction to goblet cells
In simple terms: Signals travel from immune cells to goblet cells to tell them to stop making mucus.
Following initiation, soluble mediators and cell-cell contacts transmit suppressive signals to goblet cells. SLAMF7 regulates goblet cell mucus production and negatively impacts gut homeostasis and commensalism, indicating that SLAMF7 signaling directly modulates goblet cell output. Metrnl/IL-41 inhibits macrophage extracellular traps and suppresses airway remodeling in asthma, providing an additional brake on mucus secretion.
Transcriptional and post-transcriptional control
In simple terms: The cell turns down the genes that make mucus components.
At the transcriptional level, negative regulation involves reduced expression of mucin genes and goblet cell differentiation factors. Although specific transcription factors are not fully defined for GO:0070256, the process is inferred from studies showing that SLAMF7 modulation alters goblet cell mucus production. Post-transcriptional mechanisms may include miRNA-mediated repression of mucin transcripts, but direct evidence in the context of GO:0070256 remains limited.
Inhibition of exocytosis and mucus release
In simple terms: Even if mucus is made, the cell can block its release.
The final stage of negative regulation is inhibition of mucin granule exocytosis. CD39+CD9+ macrophages and Metrnl/IL-41 signaling reduce the frequency and extent of mucus release by suppressing NETosis and extracellular trap formation. This prevents excessive mucus accumulation in the airway lumen.
Resolution and barrier restoration
In simple terms: Once mucus is controlled, the tissue barrier returns to normal.
After suppression of mucus hypersecretion, the mucosal barrier is restored. Akkermansia muciniphila protects the intestine from irradiation-induced injury by secretion of propionic acid, which supports barrier integrity and limits excessive mucus release. Plant-derived exosome-like nanovesicles represent a novel strategy for targeted oral therapy in ulcerative colitis by modulating mucus homeostasis.
Key Genes Involved in GO:0070256 negative regulation of mucus secretion
The following genes and proteins have been experimentally linked to negative regulation of mucus secretion or closely related mucus-regulatory processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CD39 (ENTPD1) | Ectonucleotidase on CD39+CD9+ lung interstitial macrophages | Suppresses IL-23/Th17-mediated neutrophilic asthma and NETosis, limiting mucus hypersecretion |
| CD9 | Tetraspanin marker on lung interstitial macrophages | Identifies a macrophage subset that negatively regulates mucus secretion |
| IL-23 | Pro-inflammatory cytokine driving Th17 responses | Its suppression by CD39+CD9+ macrophages reduces mucus secretion |
| SLAMF7 | Signaling lymphocyte activation molecule family member 7 | Regulates goblet cell mucus production and negatively impacts gut homeostasis |
| Metrnl (IL-41) | Secreted protein inhibiting macrophage extracellular traps | Suppresses airway remodeling in asthma, indirectly reducing mucus secretion |
| xCT (SLC7A11) | Cystine/glutamate antiporter | Lipid peroxidation triggered by xCT degradation contributes to pyroptosis in COPD, a disease with mucus hypersecretion |
| GSDMD | Gasdermin D, executor of pyroptosis | Mediates pyroptosis in COPD, linking cell death to mucus regulation |
| Akkermansia muciniphila | Commensal bacterium producing propionic acid | Protects intestine from irradiation-induced injury, supporting mucus barrier homeostasis |
| Intelectin-2 | Broad-spectrum antimicrobial lectin | May influence mucosal defense and mucus layer interactions |
| MUC5AC | Major airway mucin | Its expression is reduced by negative regulation of mucus secretion |
| MUC2 | Major intestinal mucin | Goblet cell mucus production regulated by SLAMF7 |
| FOXA2 | Forkhead box A2 transcription factor | Associated with goblet cell differentiation and mucus regulation |
| SPDEF | SAM pointed domain containing ETS transcription factor | Promotes goblet cell differentiation; its negative regulation reduces mucus |
| IL-4 | Type 2 cytokine | Drives mucus hypersecretion; its suppression is part of negative regulation |
| IL-13 | Type 2 cytokine | Induces goblet cell metaplasia; negative regulators counteract its effects |
| STAT6 | Signal transducer and activator of transcription 6 | Mediates IL-4/IL-13-induced mucus production; its inhibition reduces mucus |
| NF-kB | Nuclear factor kappa B | Inflammatory transcription factor; its suppression limits mucus secretion |
| NLRP3 | NOD-like receptor family pyrin domain containing 3 | Inflammasome component linked to IL-1beta-driven mucus hypersecretion |
How Is negative regulation of mucus secretion Regulated?
Negative regulation of mucus secretion is controlled by a network of immune and epithelial signals. CD39+CD9+ lung interstitial macrophages suppress IL-23/Th17-mediated neutrophilic asthma by inhibiting NETosis, thereby reducing mucus secretion. SLAMF7 regulates goblet cell mucus production and negatively impacts gut homeostasis and commensalism. Metrnl/IL-41 inhibits macrophage extracellular traps and suppresses airway remodeling in asthma. Akkermansia muciniphila-derived propionic acid protects the intestine from irradiation-induced injury, indirectly supporting mucus homeostasis. Plant-derived exosome-like nanovesicles modulate ulcerative colitis through targeted oral therapy. These pathways converge on reduced mucin gene expression and inhibited exocytosis.
negative regulation of mucus secretion and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CD39 (ENTPD1) | Neutrophilic asthma | Knockout mouse or human macrophage cell line with CD39 deletion |
| SLAMF7 | Ulcerative colitis, gut homeostasis | Intestinal organoid or goblet cell line with SLAMF7 knockout |
| Metrnl (IL-41) | Asthma airway remodeling | Airway epithelial cell line overexpressing Metrnl |
| xCT (SLC7A11) | COPD, pyroptosis | Lung epithelial cells with xCT point mutations |
| Akkermansia muciniphila | Irradiation-induced intestinal injury | Germ-free mouse model colonized with A. muciniphila |
Asthma and airway remodeling
In asthma, excessive mucus secretion contributes to airway obstruction and remodeling. CD39+CD9+ lung interstitial macrophages suppress IL-23/Th17-mediated neutrophilic asthma by inhibiting NETosis, thereby negatively regulating mucus secretion. Metrnl/IL-41 inhibits macrophage extracellular traps and suppresses airway remodeling, providing another brake on mucus hypersecretion. These findings suggest that enhancing negative regulation of mucus secretion could be therapeutic in severe asthma.
COPD and pyroptosis
Chronic obstructive pulmonary disease (COPD) is characterized by mucus hypersecretion and airway inflammation. Lipid peroxidation triggered by the degradation of xCT contributes to gasdermin D-mediated pyroptosis in COPD, linking oxidative stress and cell death to mucus dysregulation. Negative regulation of mucus secretion may counteract these processes, but direct evidence in COPD models is still emerging.
Ulcerative colitis and intestinal barrier
In ulcerative colitis, disrupted mucus barrier function exacerbates inflammation. SLAMF7 regulates goblet cell mucus production and negatively impacts gut homeostasis and commensalism, indicating that SLAMF7 modulation affects mucus secretion. Plant-derived exosome-like nanovesicles are a novel strategy for targeted oral therapy in ulcerative colitis, potentially by restoring negative regulation of mucus secretion. Akkermansia muciniphila protects the intestine from irradiation-induced injury via propionic acid, supporting mucus barrier integrity.
Primary atopic disorders
Primary atopic disorders (PAD) are monogenic conditions with severe allergic inflammation, often involving mucus hypersecretion. Rapid identification of PAD by clinical landmark-guided, upfront genomic sequencing can reveal mutations in genes that regulate mucus secretion. Understanding negative regulation of mucus secretion in PAD may guide precision therapies.
From negative regulation of mucus secretion-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CD39 in lung macrophages negatively regulate mucus secretion? | CD39 knockout mouse or CRISPR knockout in macrophage cell line |
| Does SLAMF7 loss alter goblet cell mucus production? | SLAMF7 knockout intestinal organoids |
| Can Metrnl overexpression suppress airway mucus? | Metrnl knock-in or overexpression in airway epithelial cells |
| Does xCT point mutation affect pyroptosis and mucus? | CRISPR point-mutation knock-in of xCT variants in lung cells |
| Does Akkermansia muciniphila metabolite propionic acid reduce mucus hypersecretion? | Gnotobiotic mouse model with A. muciniphila colonization |
| Can plant-derived nanovesicles restore mucus homeostasis? | Ulcerative colitis mouse model treated with nanovesicles |
How to Study the negative regulation of mucus secretion Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screening | Gene loss effects on mucus secretion | Identify negative regulators in goblet cell lines |
| RNA-seq | Transcriptional changes in mucin genes | Assess MUC5AC/MUC2 expression after perturbation |
| Proteomics | Mucus protein composition | Quantify secreted mucins and regulators |
| Immunofluorescence | Goblet cell number and mucus layer | Tissue sections from asthma or colitis models |
| PAS staining | Mucin-containing goblet cells | Airway and intestinal histology |
| ELISA | Cytokine levels (IL-23, IL-17) | Measure Th17 inflammation in asthma models |
| Organoid culture | Goblet cell function and mucus secretion | Intestinal organoids with SLAMF7 knockout |
| Flow cytometry | Immune cell populations (CD39+CD9+ macrophages) | Characterize suppressive macrophage subsets |
CRISPR knockout screening
Genome-wide CRISPR knockout screens can identify genes whose loss increases or decreases mucus secretion. For example, targeting CD39, SLAMF7, or Metrnl in relevant cell lines followed by mucus quantification can validate their roles in negative regulation of mucus secretion.
Transcriptomics and RNA-seq
RNA sequencing of goblet cells or airway epithelial cells after genetic perturbation reveals changes in mucin gene expression (MUC5AC, MUC2) and goblet cell differentiation markers, providing mechanistic insight into negative regulation of mucus secretion.
Proteomics and secretome analysis
Proteomic profiling of secreted mucus components can quantify mucin output and identify novel negative regulators. This approach is useful for studying SLAMF7 and Metrnl signaling in mucus regulation.
Imaging and histology
Immunofluorescence and periodic acid-Schiff (PAS) staining of airway or intestinal tissue can visualize goblet cell hyperplasia and mucus layer thickness, enabling assessment of negative regulation in vivo.
How CRISPR Can Be Used to Study GO:0070256 negative regulation of mucus secretion
Knockout
CRISPR knockout of candidate genes such as CD39, SLAMF7, or Metrnl in cell lines or organoids can determine whether their loss increases mucus secretion, thereby confirming their role in negative regulation of mucus secretion.
Point Mutation
Point mutations in genes like xCT (SLC7A11) can be introduced to model COPD-associated variants and assess their impact on pyroptosis and mucus secretion. This approach helps dissect specific residues required for negative regulation.
Knock-in
Knock-in of tagged versions of SLAMF7 or Metrnl allows tracking of protein localization and interaction partners in goblet cells and macrophages, providing mechanistic insight into negative regulation of mucus secretion.
Overexpression
Overexpression of negative regulators such as Metrnl or CD39 in airway epithelial cells can suppress mucus hypersecretion, offering a gain-of-function validation strategy.
How EDITGENE Supports negative regulation of mucus secretion Research
Researchers studying negative regulation of mucus secretion-related genes often need to determine whether a candidate gene is causally involved in suppressing mucus production or is merely a bystander. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that enable such causal inference.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of mucus secretion research.
Frequently Asked Questions About negative regulation of mucus secretion
What is GO:0070256 negative regulation of mucus secretion?
GO:0070256 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate or extent of the regulated release of mucus from a cell or a tissue.
What genes are involved in negative regulation of mucus secretion?
Key genes include CD39 (ENTPD1), CD9, SLAMF7, Metrnl (IL-41), and xCT (SLC7A11), as shown in studies of asthma, COPD, and gut homeostasis.
How does CD39+CD9+ lung interstitial macrophages suppress mucus secretion?
These macrophages suppress IL-23/Th17-mediated neutrophilic asthma by inhibiting NETosis, which reduces mucus hypersecretion.
What is the role of SLAMF7 in mucus regulation?
SLAMF7 regulates goblet cell mucus production and negatively impacts gut homeostasis and commensalism.
How does Metrnl/IL-41 affect airway mucus?
Metrnl/IL-41 inhibits macrophage extracellular traps and suppresses airway remodeling in asthma, indirectly reducing mucus secretion.
Is negative regulation of mucus secretion relevant to COPD?
Yes, lipid peroxidation triggered by xCT degradation contributes to gasdermin D-mediated pyroptosis in COPD, a disease with mucus hypersecretion.
Can CRISPR be used to study negative regulation of mucus secretion?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models can validate genes like CD39, SLAMF7, and Metrnl in mucus-secreting cells.
What diseases are linked to defective negative regulation of mucus secretion?
Asthma, COPD, ulcerative colitis, irradiation-induced intestinal injury, and primary atopic disorders have been linked to dysregulated mucus secretion.
How does Akkermansia muciniphila affect mucus secretion?
Akkermansia muciniphila protects the intestine from irradiation-induced injury by secretion of propionic acid, supporting mucus barrier homeostasis.
What research methods are used to study GO:0070256?
Common methods include CRISPR screening, RNA-seq, proteomics, immunofluorescence, PAS staining, ELISA, organoid culture, and flow cytometry.
Conclusion
GO:0070256 (negative regulation of mucus secretion) is an essential biological process that restrains excessive mucus release and maintains mucosal homeostasis. Key regulators such as CD39+CD9+ macrophages, SLAMF7, and Metrnl/IL-41 have been implicated in asthma, COPD, and intestinal inflammation. CRISPR-based models are powerful tools to causally dissect these pathways and identify new therapeutic targets. EDITGENE offers comprehensive CRISPR services to accelerate research on negative regulation of mucus secretion.
References
- 1. Han S et al.. 2024. Distinctive CD39(+)CD9(+) lung interstitial macrophages suppress IL-23/Th17-mediated neutrophilic asthma by inhibiting NETosis.. Nat Commun 15(1):8628 PMID: 39366998
- 2. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 3. He KY et al.. 2023. Akkermansia muciniphila protects the intestine from irradiation-induced injury by secretion of propionic acid.. Gut Microbes 15(2):2293312 PMID: 38087436
- 4. Ning H et al.. 2025. Plant-Derived Exosome-Like Nanovesicles: A Novel Strategy for Targeted Oral Therapy in Ulcerative Colitis.. Int J Nanomedicine 20:10595-10611 PMID: 40927660
- 5. Hou T et al.. 2024. Lipid peroxidation triggered by the degradation of xCT contributes to gasdermin D-mediated pyroptosis in COPD.. Redox Biol 77:103388 PMID: 39374556
- 6. Zhou D et al.. 2025. SLAMF7 regulates goblet cell mucus production and negatively impacts gut homeostasis and commensalism.. Gut Microbes 17(1):2527857 PMID: 40646691
- 7. Dugan AE et al.. 2026. Intelectin-2 is a broad-spectrum antimicrobial lectin.. Nat Commun 17(1):231 PMID: 41530121
- 8. Feng K et al.. 2025. Inhibition of macrophage extracellular traps by Metrnl/IL-41 suppresses airway remodeling in asthma.. Biochem Pharmacol 242(Pt 1):117288 PMID: 40885323
